Background: Markers of inflammation (e.g. interleukin-6[IL-6]), and endothelial perturbation
INTRODUCTION
The endothelium plays a critical role in the pathogenesis of vascular disease. Endothelial dysfunction implies functional alterations in physiological integrity and may be assessed by tests on pharmacological-or shear stress-induced endothelium-dependent vasodilatation and on plasma markers of endothelial perturbation (1) . However, endothelial dysfunction can perhaps be distinguished from endothelial damage, as the latter may be represented by the anatomical disruption, or even detachment, of the endothelium from the vascular internal elastic lamina (1, 2) .
Recently, a novel method for assessing endothelial damage, as circulating endothelial cells (CECs) in the peripheral blood, has been developed (3) . Increased CECs in the peripheral blood have been reported in various pathological conditions involving severe endothelial perturbation, including inflammatory disease, acute myocardial infarction, unstable angina and critical limb ischaemia (3) (4) (5) . The demonstration of an increased numbers of CECs may be the most direct evidence of endothelial injury/damage in these conditions, and perhaps also reflects the degree of severity of the insult(s) towards the endothelium, especially since these cells are rarely found in the blood of healthy persons. Thus, increased numbers of CECs may yet be a prognostic indicator in patients with vascular disease, but (as far as we are aware) this is still unproven.
However, CECs are not the only index of endothelial perturbation. Plasma von Willebrand factor (vWf, marking endothelial damage/dysfunction) may contribute directly to thrombosis, is increased in all major risk factors for atherosclerosis and in clear cardiovascular disease, and increased levels predict poor long-term outcome (1, 6, 7) . Acute changes in vWf levels are also important. For example, in patients with non-ST elevation myocardial infarction (non-STEMI) or unstable angina pectoris (UAP), increasing plasma vWf and anther molecule relevant to 5 thrombosis and haemostasis (i.e. plasminogen activator inhibitor) levels during the first 48 hours of presentation to hospital are an independent predictor of adverse cardiovascular outcomes at 14-days' and 30-days' follow-up (8) (9) (10) .
Recently, attention has also focused on the potential role of plasma markers of inflammation as predictors of cardiovascular events (11) . Elevated levels of the proinflammatory cytokine interleukin-6 (IL-6) at 48 hours after presentation with acute coronary syndromes (ACS) have been shown to be closely associated with an adverse in-hospital prognosis, even without a rise in serum troponin T (12) . Similarly, increasing levels of IL-6 over the first 72 hours of hospitalisation were a powerful predictor of 30-day outcomes in patients presenting with non-STEMI or UAP, when compared to the other plasma indices, including vWf (13).
We hypothesised that increased baseline plasma IL-6 and the numbers of CECs and/or increasing levels of these markers during the first 24 -48 hours of presentation (i.e. an 'acute release', ) predict short-as well as long-term major adverse cardiovascular events (MACE) in patients with acute coronary disease. To test this hypothesis, we studied consecutive patients admitted with ST elevation myocardial infarction (STEMI), non-STEMI or UAP -and used levels of vWf [previously shown to rise under these conditions (8-10)], as a comparator and 'positive control'.
A sub-hypothesis stated that there was a difference in the research indices according to STEMI or non-STEMI status. For disease-specific comparative purposes and to provide a perspective, we compared levels in ACS to patients with clinically stable coronary artery disease (CAD) and healthy controls, and stained CECs for leukocyte, progenitor and other markers.
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METHODS
Subjects
Patients consecutively admitted to our Coronary Care Unit with chest pain or discomfort at rest, associated with ST-segment and/or T-wave changes on a standard electrocardiogram (ECG) occurring within 24 hours of their symptom onset were prospectively recruited. The diagnosis of STEMI was defined as the concurrence of prolonged chest pain/discomfort with persistent STsegment elevation of >1mm in two or more contiguous leads or with presumed new left bundlebranch block with cardiac enzymes (total creatine kinase [CK] and MB creatine kinase [CK-MB]) above twice the upper normal limit (14) . The diagnosis of non-STEMI included the presence of typical angina at rest associated with acute and transient ST-segment or T-wave changes with cardiac enzymes above twice the upper normal limit and/or raised troponin I levels to at least 'high risk' values (>0.6 ng/ml) (14) . Patients with clinical/ECG features of non-STEMI but with normal cardiac enzymes plus normal troponin levels were classified as UAP. All patients received standard therapy included aspirin, low molecular weight heparin, intravenous nitrates, statin, beta-blocker, angiotensin converting enzyme (ACE) inhibitor etc where appropriate. The global risk profile of the patients on admission was also assessed with the Thrombolysis In Myocardial Infarction (TIMI) risk score for STEMI (15) and for UAP/Non-STEMI (16) . One modification was made to apply the risk score in the present study -a history of MI, percutaneous coronary intervention (PCI), or coronary bypass grafting (CABG) surgery was substituted for known coronary artery stenosis >50%.
Baseline values of vWf, IL-6 and CECs of acute patients were compared with 36 age-and sexmatched patients with clinically stable coronary artery disease (CAD) and 40 healthy controls.
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Stable CAD patients were recruited from those who had recently completed a 12-week course of cardiac rehabilitation programme in our hospital for previous (>3 months) MI or coronary revascularisation. Healthy controls, defined by careful history, examination and basic blood tests, were recruited from members of the hospital staff and from those relatives attending the hospital cardiac rehabilitation with the stable CAD patients. These subjects were asked to abstain from tobacco and alcoholic and caffeine-containing beverages during the evening before blood sampling.
None of the acute or stable patients or healthy controls had a history of renal or liver disease, malignancy, connective tissue disease, deep vein thrombosis or pulmonary embolism, recent infections, inflammatory disorders, or were taking regular non-steroidal anti-inflammatory drugs or on anticoagulants. To avoid possible influences of percutaneous coronary intervention (PCI) or catheter-related acute-phase reactions on the measured parameters, patients requiring urgent PCI or coronary angiographic investigation within the first 48 hours of admission were excluded from this study. Informed consent was obtained from all patients and controls. The protocol was approved by the local ethical committee.
Clinical follow-up
All acute patients were followed up for major adverse cardiovascular events (MACE), defined as the occurrence, at 30 days and 1 year, of a composite end point of cardiovascular death, non-fatal MI, or refractory angina with ECG ST-T segment changes requiring hospitalisation or urgent coronary revascularisation. Non-fatal MI was defined by a history of angina with ST-T segment changes on ECG and elevated cardiac enzyme (total CK and CK-MB levels above twice the 8 upper normal limit or raised troponin levels to >0.6 ng/ml) (14) . Patients with events occurring between admission and the 48-hour sampling were excluded from the analysis.
Blood samples and laboratory analyses
Blood was drawn on admission (baseline) and 48 hours thereafter. The first 4 ml of blood were discarded. All samples for plasma were immediately placed on ice and were centrifuged at 3000 rpm/1000g at 4ºC for 20 min within 1 hour of collection to obtain citrated plasma. Plasma were divided into aliquots and stored at -70ºC to allow batch analysis. All laboratory work was performed in blinded fashion with respect to the identity of the samples and clinical events.
vWf and IL-6 levels were measured in duplicate by ELISA using commercial reagents (DakoPatts, Ely, UK and R&D Systems, Abingdon, UK, respectively). The lower limits of detection were 0.5 IU/dl for vWf and 5 pg/ml for IL-6. Intra-assay and inter-assay coefficients of variation (CVs) were <5% and <10%, respectively. Blood for CECs was collected in sodium fluoride and prepared for immunomagnetic separation within 1 hour and counted by a single observer under epifluorescence microscopy (Zeiss, Welwyn Garden City, Herts, UK). The detailed methodology for capturing CECs (using anti-CD146-coated immunomagnetic Dynabeads TM , Dynal, Warrington, Cheshire, UK) and criteria for counting CECs has been described in detail elsewhere (4;5). Intra-(n=40) and inter-assay (n=20) CVs were <5% and <10% respectively; the inter-and intra-observer CVs of the method in our laboratory were <5% (5). 
Power calculations
Previous data from 68 ACS patients indicated that the change of vWf levels during the first 48 hours was about 2-fold higher in patients who experienced a 30-day endpoint (n=27, 40% of patents) than in those without an endpoint (p=0.02). At 1-year follow up, 38 patients (56%) had at least one endpoint (8;9). However, we more conservatively predicted that only 30% of our cohort would experience at least one endpoint at 1-year follow-up, and because we intended to measure and assess several indices, we decided to recruit over twice as many patients (i.e. to n=156). As this number of patients far exceeds our previous data showing raised CECs in ACS (4) and critical limb ischaemia (5), we are therefore confident of minimising the risk of types 1 and 2 error. Of the 156 patients, 68 had STEMI and 44 non-STEMI, providing the 1-power of 0.8 to detect a 1p<0.05 difference of 0.4 of a standard deviation in a continuously-distributed variable index such as vWf. We also recruited 36 patients with stable CAD and 40 healthy controls to provide perspective. As these subjects do not test a hypothesis, a power calculation is not needed although the numbers provide as much power as our previous CEC data (4;5).
Statistical analysis
The Anderson-Darling test was applied to continuously variable data to define distribution. and clinical variables that have a P value <0.20 in the univariate procedure. The odds ratios (ORs) with their 95% confidence intervals (CIs) of each significant predictor were computed.
The comparisons for cumulative probability of event-free survival between patients in the median and <median values (i.e. high versus low levels) of each measured indices were performed using Kaplan Meier survival analyses with log-rank test. Cox stepwise regression was used to test predictors of adverse outcome at 1 year, adjusted for known cardiovascular risk factors (age, sex, active smoking, body mass index, past history of stroke or transient ischaemic attack, congestive heart failure, hypertension, diabetes mellitus, family history of CHD) and the basal values of the biological indices, including cardiac enzyme rise, etc. All tests were 2-tailed, and probability values were considered significant at the 0.05 level. All statistical analyses were performed using SPSS software, version 11 (SPSS Inc., Chicago, Illinois, USA).
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RESULTS
Cross-sectional Data
The demographic, clinical and baseline research data from the 156 patients with ACS, the 36 with stable CAD and the 40 healthy controls are shown in Table 1 . As expected (4;5;8-13), the baseline CECs (Figure 1 ), vWf and IL-6 levels in the patients with ACS were higher than the patients with stable CAD and the healthy controls. Table 2a .
There were no statistically significant differences in demographic and clinical variables, the use of standard in-patient therapy and secondary preventive medications at discharge. Patients who experienced a MACE had significantly higher TIMI risk scores on admission for both STEMI (p=0.023) and Non-STEMI/UAP (p=0.02).
The baseline, 48hr and in vWf, IL-6 and CECs according to 30-day MACE are shown in Figure 3 . Baseline, 48hr and CECs, IL-6, and 48hr and vWf were higher in those with a MACE at 30 days. In multivariate logistic regression controlling for heart rate, systolic blood 
DISCUSSION
Montalescot and colleagues have amply and elegantly demonstrated that raised vWf in the peri-ACS period predicts MACEs (8-10). We confirm their data, but also show that IL-6 and another vascular index, CECs, are also valuable in predicting those at risk of a MACE. In patients with acute coronary disease, particularly those with myocardial damage, elevated numbers of CECs can be readily demonstrated (4, 5) . The present study confirms these observations and in addition, also shows for the first time that among the measured indices, elevated numbers of CECs are the only independent predictor of death at 30 days and at 1 year. Taken together, these results suggest that serious damage and increasing shedding of the vascular endothelium into the circulation during the initial period of the coronary ischaemic insult may in part play a role in the short-and long-term pathogenesis of recurrent cardiovascular events.
The pathophysiological basis of ACS includes thrombosis, haemostasis and disturbed vascular function, with rupture of a vulnerable plaque, leading to exposure of the blood constituents to the sub-endothelial surface and plaque core (17, 18) . The resultant thrombosis leads to a variable degree of flow occlusion, the extent of which (possibly) differentiates the three acute coronary syndromes, STEMI, non-STEMI and UAP. These in turn may lead to a variable degree of disruption and shedding of the endothelium, presumably from the infarct-related coronary artery and its territorial endomyocardium. Indeed, if the risk factor theory of cardiovascular disease is correct, then many mural and/or intra-cardiac endothelial cells will be damaged before these acute events, and thus easier to remove and so transform into CECs by the process of infarction and/or spasmosis. Increased vWf in subjects with chronic disease and/or risk factors (reviewed in ref 1) , and raised CECs in 'atherosclerosis-free' pulmonary hypertension (19) probably reflect a greater degree of endothelial injury/damage associated with the more severe ischaemic insult in the former group. Given the importance and diversity of physiological functions of the endothelium, it seems likely that a greater degree of endothelial dysfunction/injury/damage can lead to a greater degree of thrombosis and disturbed blood flow (1, 2) , and thereby, constitute the higher recurrent MACE rate observed in STEMI and non-STEMI patients than in UAP patients.
The potential for CECs to participate in additional disease such as thrombosis and microinfarction has been previously suggested in studies of patients in acute crises in sickle cell anaemia (20) (21) (22) and in patients with systemic lupus erythematosus (SLE) (23) . Once shed, CECs, if viable, may be capable of further potentiating vascular injury by the production of prothrombotic mediators (e.g. vWf, tissue factor) and engaging in heterotypic aggregation with neutrophils or platelets, with resultant vascular thrombosis (20) (21) (22) (23) . Indeed, acute inflammation (IL-6), endothelial cell activation, damage and dysfunction (vWf) are closely related determinants of the onset and course of acute coronary disease (24) . Thus our results are consistent with previous studies indicating that the acute release of IL-6 (12;13) and vWf (8-10) during the first 48 hours of presentation of ACS were significant independent predictors of adverse events at 30 days. In addition, we also show that the acute release of IL-6, a proinflammatory cytokine, is an independent predictor of adverse events at 1 year follow-up. Further support for the role of vWf and IL-6 in the course of acute coronary disease are the strong correlations between the numbers of CECs and the levels of vWf and IL-6. However, the precise mechanisms underlying interactions between vWf, IL-6 and CECs in the pathogenesis of recurrent cardiovascular event are unclear, probably complex and certainly require further investigation (25) .
Several studies and reviews have addressed the origin and cellular nature of CECs (3) (4) (5) (20) (21) (22) (23) (25) (26) (27) and their relation to endothelial progenitor cells (EPC) (25, (28) (29) (30) (31) (32) . In this study, and our previous studies, CECs were defined using an endothelial specific antigen CD146 which is almost exclusively expressed on mature endothelial cells (3;26) . Furthermore, we found CECs to be almost entirely eNOS-staining positive, but effectively CD31 (PECAM-1), CD34 (EPC), CD36 (microvascular cells) and CD45 (leukocyte common antigen) negative. Thus, we assume that our cells are mural-endothelial in origin (eNOS being endothelial specific) and simply not just part of a repair process because EPC derived from the bone marrow are CD146 negative and CD34 positive (28) (29) (30) . However, we acknowledge the possibility that as CD34 negative circulating cells may differentiate into endothelial cells ex vivo they may have a role in the repair process in vivo (29, 30) . Further studies of CEC phenotypes are required to elucidate the pathogenesis of endothelial cell damage.
Finally, although it is clear that CECs are a novel tool in the assessment of endothelial cell damage, there are other such tools. Other investigations of endothelial dysfunction and injury in patients with CAD have used plasma increased vWf, thrombomodulin and E-selectin alongside impaired brachial artery flow-mediated (endothelium-dependent) dilatation (FMD) (1,2) . Indeed, Solovey et al (22) used cell surface thrombomodulin to help define their CD146+ve CECs. Our present and previous studies have found strong relationship between numbers of CECs and vWf levels (5) and inversely between FMD and vWf (33) . Recently, increased CD146+ve and annexin V+ve (i.e. apoptotic) CECs have been inversely correlated with brachial artery FMD and elevated tissue factor in young females with SLE (34). Our recent case-control study of congestive heart failure reports also an inverse correlation between FMD and CECs (r = -0.423, p=0.002), alongside positive relationships between FMD and vWf (r = -0.461, p=0.001) and between CECs and vWf (r = 0.29, p=0.032) (35) . These data provide additional support for the concept of CECs as an additional marker of endothelial perturbation.
In conclusion, the present study suggests increased and increasing numbers of CECs in patients with acute coronary syndromes could be indicative of the severity of the ischaemic episode and progressive of active disease, respectively. Despite the overwhelming mass of data on the vascular origin of CD146+ve CECs, a very minor doubt remains as some spleen cells may coexpress several relevant markers (36) . Nevetheless, our data suggest that numbers of CECs, which are closely associated with high vWf and IL-6 levels, may be a novel prognostic indicator of both short-and long-term adverse events in acute vascular disease. (23) 22 (49) 13 (27) 4 (8) 9 (19) 2 (4.2) 23 (21) 4 (4) 13 (12) 32 (30) 48 (44) 32 (30) 5 (5) 25 (23) Inter-group comparisons *P<0.001; MACE, major adverse cardiovascular events; vWf, von Willebrand factor; IL-6, interleukin-6; CEC, circulating endothelial cells. 
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